{
  "meta": {
    "timestamp": "2025-01-06T14:19:54.251412",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Keros Therapeutics Inc.",
      "symbol": "KROS",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Clinical trial risks, including safety concerns and potential delays in drug development",
            "Regulatory and legal challenges, including investigations for potential securities fraud",
            "Financial dependence on external funding and milestone payments",
            "Highly competitive biopharmaceutical sector with uncertain market differentiation"
          ],
          "controversies": [
            "Voluntary halt of dosing in Phase 2 TROPOS trial due to safety concerns",
            "Ongoing investigations by law firms for potential securities fraud allegations"
          ],
          "environmental_issues": [],
          "social_issues": [],
          "governance_issues": [
            "Potential legal liabilities and reputational damage from ongoing investigations"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Takeda to License Elritercept from Keros Therapeutics",
              "snippet": "Takeda will be responsible for all development, manufacturing and commercialization as of the effective date of the agreement. Takeda will provide Keros Therapeutics with an upfront payment of $200 million and potential payments relating to regulatory, development and commercial sales milestones, as well as royalties on net sales.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501938+00:00",
              "published_date": null,
              "source_hash": "c49f3e5f2ee0389fd951e137be3b6be2"
            },
            {
              "url": "",
              "title": "Keros Therapeutics Announces Global License Agreement with Takeda to ...",
              "snippet": "Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered royalties on net sales LEXINGTON, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:30.394928+00:00",
              "published_date": null,
              "source_hash": "99c1fe3e95e8f0bca7aff9100427ce9e"
            },
            {
              "url": "",
              "title": "Keros Therapeutics Announces Global License Agreement with Takeda to ...",
              "snippet": "Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501917+00:00",
              "published_date": null,
              "source_hash": "c601fec43971ae3642c8bb9253f46e54"
            },
            {
              "url": "",
              "title": "Keros shares plunge as safety doubts prompt dosing pause in blood ...",
              "snippet": "Keros Therapeutics said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a mid-stage study after reports of a safety issue, sending its shares ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:26.380633+00:00",
              "published_date": null,
              "source_hash": "04a6ad24be01d30c006c3ca39614157d"
            },
            {
              "url": "",
              "title": "Takeda Strengthens Oncology Pipeline with Elritercept through Licensing ...",
              "snippet": "OSAKA, Japan & CAMBRIDGE, Mass., December 03, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:26.380642+00:00",
              "published_date": null,
              "source_hash": "62f9ee3e8f5d55627367c9370ffe9ac8"
            },
            {
              "url": "",
              "title": "Keros Therapeutics Halts Dosing In Phase 2 Trial Of Cibotercept ...",
              "snippet": "Biopharmaceutical company Keros Therapeutics, Inc. announced Thursday that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.TROPOS trial is a Phase 2 clinical trial of cibotercept (KER-012) in combination with background ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:26.380662+00:00",
              "published_date": null,
              "source_hash": "7c454c7b29b33d6c5e0c917ee0ea582d"
            },
            {
              "url": "",
              "title": "Takeda licensed for anaemia therapy by Keros Therapeutics",
              "snippet": "The company will pay Keros $200m upfront and potentially $1.1bn in development, approval, and sales milestones. Keros is also eligible for tiered royalties on net sales. The agreement's activation is contingent upon clearance under the US's Hart-Scott-Rodino Antitrust Improvements Act. ... Keros Therapeutics CEO and chair Jasbir Seehra ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:26.380674+00:00",
              "published_date": null,
              "source_hash": "6892c7c8b05b4e7c1df3f911cbe478b3"
            },
            {
              "url": "",
              "title": "Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood ...",
              "snippet": "Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. Meanwhile, the Takeda deal enables Keros to focus on two wholly ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:26.380683+00:00",
              "published_date": null,
              "source_hash": "68fbcf5d812adb280731f5de00125b67"
            },
            {
              "url": "",
              "title": "Takeda Strengthens Oncology Pipeline with Elritercept through Licensing ...",
              "snippet": "Takeda will be responsible for all development, manufacturing and commercialization as of the effective date of the agreement. Takeda will provide Keros Therapeutics with an upfront payment of $200 million and potential payments relating to regulatory, development and commercial sales milestones, as well as royalties on net sales.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:26.380691+00:00",
              "published_date": null,
              "source_hash": "d935cb3bebdb3a7f0b67189e09791618"
            },
            {
              "url": "",
              "title": "Keros Therapeutics Inc | Reuters",
              "snippet": "Keros Therapeutics said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a mid-stage study after reports of a safety issue, sending its shares ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501969+00:00",
              "published_date": null,
              "source_hash": "90ce06a609c8d523c350d801fce4eaf9"
            },
            {
              "url": "",
              "title": "Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - KROS",
              "snippet": "NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:37.157293+00:00",
              "published_date": "2025-01-06T17:19:00+00:00",
              "source_hash": "75755eba253bbcb0ac5d1c01e74e5ff6"
            },
            {
              "url": "",
              "title": "Bank of America Securities Sticks to Its Buy Rating for Keros Therapeutics (KROS)",
              "snippet": "In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Keros Therapeutics (KROS - Research",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:37.157370+00:00",
              "published_date": "2025-01-06T11:38:00+00:00",
              "source_hash": "15786f590c13d05e72059aa1cf5ffc97"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS",
              "snippet": "NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. (\"Keros\" or the \"Company\") (NASDAQ: KROS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:37.157382+00:00",
              "published_date": "2025-01-03T17:08:00+00:00",
              "source_hash": "2dd411bdf745d25529ae220bbe7854f3"
            },
            {
              "url": "",
              "title": "Keros Therapeutics, Inc. (KROS)",
              "snippet": "approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered royalties on net sales LEXINGTON, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:28.859807+00:00",
              "published_date": "2024-12-14T00:59:00+00:00",
              "source_hash": "1e91a238d825990e4006b98878e625a5"
            },
            {
              "url": "",
              "title": "Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff",
              "snippet": "Keros Therapeutics, Inc.'s stock plummeted over 75% due to ... Seemingly, Pharma giant Merck's sotatercept, now approved to treat PAH as Winrevair, caused a case of Pericardial effusion in a ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:28.859816+00:00",
              "published_date": "2024-12-12T13:32:00+00:00",
              "source_hash": "edbb19a00ee475a107bc47c46ae91179"
            },
            {
              "url": "",
              "title": "Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi ...",
              "snippet": "Keros issued a press release on December 12, 2024, \"announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501779+00:00",
              "published_date": null,
              "source_hash": "bf78be6d00a5744f3e29e7e45d1c5ab6"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims ... - Morningstar",
              "snippet": "On December 12, 2024, Keros issued a press release \"announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:30.394871+00:00",
              "published_date": null,
              "source_hash": "b141ab346fb798d2dfa855254a0fcf9d"
            },
            {
              "url": "",
              "title": "Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics ...",
              "snippet": "On December 12, 2024, Keros issued a press release \"announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (\"PAH\"), based on a safety ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:30.394886+00:00",
              "published_date": null,
              "source_hash": "1dfebc467dfb91c84904c8af8694d718"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of ...",
              "snippet": "NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. (\"Keros\" or the \"Company\") (NASDAQ: KROS). Such investors are ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:30.394898+00:00",
              "published_date": null,
              "source_hash": "569dbece4b0fb44c5bc802a51372e100"
            },
            {
              "url": "",
              "title": "2025-01-06 | SHAREHOLDER ALERT: Pomerantz Law Firm ... - Stockhouse",
              "snippet": "NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. (\"Keros\" or the \"Company\") (NASDAQ:KROS).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.. The investigation concerns whether Keros and certain of its officers and/or directors have engaged in ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:30.394907+00:00",
              "published_date": null,
              "source_hash": "fc0ca1519b42201b21ffd05757fd4641"
            },
            {
              "url": "",
              "title": "Keros Plunges After Dosing Halted in Lung Drug Trial on Safety",
              "snippet": "Keros Therapeutics Inc. shares plunged after the biotech company halted dosing for some patients in a mid-stage trial of its lung disorder drug over side effect concerns.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:30.394918+00:00",
              "published_date": null,
              "source_hash": "6cabba3944627cfa18a712bdc71811f8"
            },
            {
              "url": "",
              "title": "Keros Therapeutics: How To Respond To Today's Major Safety Setback And ...",
              "snippet": "Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer stability. Click for more on KROS.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:30.394939+00:00",
              "published_date": null,
              "source_hash": "3e09646cfc14bb4fae2fe1f836e25ada"
            },
            {
              "url": "",
              "title": "Keros Therapeutics Reports Recent Business Highlights and Third Quarter ...",
              "snippet": "LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (\"Keros\" or the \"Company\") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (\"TGF-\u00df\") family of proteins ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501926+00:00",
              "published_date": null,
              "source_hash": "d531a0d9e74c4a1230114edb536af256"
            },
            {
              "url": "",
              "title": "Takeda to License Elritercept from Keros Therapeutics",
              "snippet": "I am excited to further advance the pioneering work begun by the Keros Therapeutics team with the goal of delivering this potential treatment option to patients.\" Elritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low- or intermediate-risk MDS and one in patients with MF.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:30.394960+00:00",
              "published_date": null,
              "source_hash": "ae2862ac66a24ad5eeee66ccb2ccfef2"
            },
            {
              "url": "",
              "title": "Keros Therapeutics, Inc. (KROS)",
              "snippet": "Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (\"Keros\" or the \"Company ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:37.157393+00:00",
              "published_date": "2024-12-14T00:59:00+00:00",
              "source_hash": "1f5c777827114c78da0e3322e5203c42"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS",
              "snippet": "NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. (\"Keros\" or the \"Company ... arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012 ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:32.881873+00:00",
              "published_date": "2025-01-03T17:08:00+00:00",
              "source_hash": "96a852cdbd741aaecb1c2c2a2e9c1e77"
            },
            {
              "url": "",
              "title": "Keros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A Rebound",
              "snippet": "Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, after the company halted two high-dose arms in its Phase 2 TROPOS trial ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:32.881883+00:00",
              "published_date": "2024-12-12T15:58:00+00:00",
              "source_hash": "f710a9d0a6e3351a7029f6c9c88b9dd1"
            },
            {
              "url": "",
              "title": "Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff",
              "snippet": "Keros Therapeutics, Inc.'s stock plummeted over 75% due ... mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:19:32.881894+00:00",
              "published_date": "2024-12-12T13:32:00+00:00",
              "source_hash": "e8947461872ba0e1912df258d93949b0"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims ... - Morningstar",
              "snippet": "NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. (\"Keros\" or the \"Company\") (NASDAQ: KROS). Such investors are ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501884+00:00",
              "published_date": null,
              "source_hash": "6dff562b0358d42bf09430f264bcdaf6"
            },
            {
              "url": "",
              "title": "Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics ...",
              "snippet": "Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501896+00:00",
              "published_date": null,
              "source_hash": "e928c13d0ac25663c4705d9096cdcc35"
            },
            {
              "url": "",
              "title": "Keros Therapeutics Announces Global License Agreement with - GlobeNewswire",
              "snippet": "About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501907+00:00",
              "published_date": null,
              "source_hash": "3543bafcc352332e436d0d88fed8c6c8"
            },
            {
              "url": "",
              "title": "Takeda licensed for anaemia therapy by Keros Therapeutics",
              "snippet": "Keros Therapeutics CEO and chair Jasbir Seehra stated: \"We are excited to partner with Takeda, whose global reach and expertise in oncology and haematology will help unlock elritercept's potential for patients with myelodysplastic syndromes (MDF) and myelofibrosis (MF) [rare types of anaemia-related blood (haematologic) cancers].",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501949+00:00",
              "published_date": null,
              "source_hash": "d38522957b591dd1019a01ffc62f455c"
            },
            {
              "url": "",
              "title": "Keros Therapeutics, Inc. - Drug pipelines, Patents, Clinical ... - Patsnap",
              "snippet": "About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-\u00df family of proteins. ... maintain and protect its intellectual property; and Keros' dependence ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:34.501958+00:00",
              "published_date": null,
              "source_hash": "fd212bd24dd9f2ce9558924a6d7de397"
            },
            {
              "url": "",
              "title": "Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $81.33",
              "snippet": "Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus rating of \"Moderate Buy\" by the fourteen ratings firms that are currently covering the company, MarketBeat Ratings reports.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Keros Therapeutics Inc. Keros Therapeutics Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:19:37.157401+00:00",
              "published_date": "2024-12-21T05:34:00+00:00",
              "source_hash": "3ad488453dedac2be63af7b2d7534639"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Keros Therapeutics Inc. regulatory approval delays",
              "rationale": "Investigate potential delays or rejections in regulatory approvals for KER-050 and KER-047",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Keros Therapeutics Inc. clinical trial failures",
              "rationale": "Examine any reported failures or safety issues in ongoing Phase 2 trials for KER-050 and KER-047",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Keros Therapeutics Inc. intellectual property disputes",
              "rationale": "Assess any ongoing or past disputes related to the company's IP portfolio and proprietary technologies",
              "priority": 2
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:19:54.251421",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}